CatSci further strengthens its material science, analytical science and preformulation capabilities with a £3 million investment

Written by: Editor
Published on: 24 Feb 2021

Cardiff, UK - CatSci, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, is expanding its capabilities in material science, analytical science and preformulation studies to better serve its customers’ needs. This expansion will be supported by a £3 million investment over the next two years and the opening of a secondary site in Dagenham, Essex, in April 2021. The new facility will help to increase the UK’s scientific exports and solidify the UK as a centre for excellence in pharmaceutical research and development (R&D).

CatSci’s enhanced capabilities will include addressing new modalities and asset classes, such as oligonucleotides, alongside additional capacity for GMP analytical testing. By adding better solid form characterisation to its material science offerings and increasing its preformulation capabilities, CatSci aims to break down the barriers between drug substance and drug product to improve medicines development. By following a science-led approach, with the end product in mind, CatSci will expedite the development and launch of new medicines.

To lead these expansion plans, CatSci has appointed Dr Nigel Richardson as the Director of Analytical Technology and New Modalities and Dr Robert Dennehy as Director of Crystallisation and Solid State.

Dr Richardson will also take up the position of Site Director at the new analytical facility in Dagenham, utilising his expertise in analytical technology, oligonucleotide development and previous role as Senior Director within the CMC Analytical Division at GlaxoSmithKline (GSK).

Dr Dennehy, whose experience includes leading the Particle Sciences team at GSK,  will develop the workflows for CatSci’s material science lab and act as a consultant for the transformation of CatSci’s solid form capabilities.

The facility and capabilities expansion will help CatSci on its path to becoming a fully integrated CMC company, one that continually evolves to provide ‘more and better’ for customers bringing best-in-class therapeutics to patients in need. It also follows the current trend for expansion within the buoyant UK based life science sector. Innovation in this area will create more jobs and help to solidify the UK as a key player in the global pharmaceutical development industry.

Dr Ross Burn, CEO, said: “It is a fantastic time to be expanding our business in the UK pharmaceutical R&D space. These increased capabilities will significantly contribute to CatSci’s current offerings and will be a continuation of the already successful £1.3 million expansion we’ve just completed. We’re confident that this next step will offer strategic value to our customers’ journey from molecule to medicine and strengthen the UK economy.”

Dr Robert Dennehy, Director of Crystallisation and Solid State said: “I’m honoured to be a part of this next stage in CatSci’s evolution, applying my expertise in solid state to accelerate the development of life-changing therapeutics.”

Dr Nigel Richardson, Director of Analytical Technology and New Modalities, said: “It’s a really exciting time to be working in the process R&D and life sciences sector. I’m delighted to be helping CatSci to deliver excellence in measurement science so that our customers can make the right decisions first time and every time.”

About CatSci

CatSci Ltd is an award-winning innovation partner for medicines development, dedicated to developing economically and environmentally sustainable pharmaceutical manufacturing processes. We proudly serve customers across the globe, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies including catalysis, material science and analytical development.

Agile, commercially-minded and scientifically-led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class small molecule therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.

CatSci works efficiently with your preferred partners, while continually strengthening our own industry-leading partnerships across the pharmaceutical supply chain, to address your dynamic drug substance development needs. A true extension of your team, we are a dependable, trusted partner for innovation that takes the time to understand your project objectives and provide you with perfect-for-purpose solutions.

Recognition includes wins at the prestigious CPhI Pharma Awards (Excellence in Pharma: Contract Services and Outsourcing), at the highly esteemed Cardiff Business Awards (International Business of the Year) and the Wales STEM 2020 Awards (STEM scale-up of the year). We were also recently shortlisted for the International Expansion Entrepreneur of the Year at the Barclays Entrepreneur Awards 2020 and the 2020 Bionow Export Award.

https://catsci.com/

Follow us on Twitter and LinkedIn

© CatSci Ltd, 2021.

Related links